Cancer & Oncology

A research explainer on an Mn(II)-coordinated peptide nanoassembly evaluated in 4T1 cells, dendritic cells, and a murine breast cancer model.

Research explainer on prospective comparison of fully automated AI and expert global longitudinal strain assessment during cardiotoxic breast cancer treatment.

A research explainer of a preclinical proof-of-concept that uses collagenase-integrated iron-oxide nanotransformers to promote tumor penetration, lysosomal aggregation, ferroptosis, and reported antitumor immune responses.

A three-patient exploratory subanalysis examined serial FDG PET/CT after sipuleucel-T, with or without IL-7, in metastatic castration-resistant prostate cancer.

A research explainer on evidence that gut bacteria can transform flutamide into metabolites that lacked anticancer activity in the reported prostate-cancer cell-line assays.

A prospective PLCO cohort analysis associated higher HEI-2020 diet-quality scores with a decreasing trend in colorectal cancer incidence and lower colorectal cancer-specific mortality, without establishing causation.

A cross-sectional analysis linked higher perceived socioeconomic standing with better quality of life among 99 middle- and older-aged women after breast-cancer surgery and before adjuvant therapy.

A preclinical mouse study evaluated irreversible electroporation paired with macrophage-membrane-coated nanogels designed to use a temporary immune and inflammatory tumor state.

A single-center retrospective study in adults with sickle cell disease found an association between embedded primary care and higher cervical cancer screening adherence, alongside several other preventive-care measures.

A preclinical research explainer of a dendritic-cell-targeted, pH-responsive lipid nanoparticle designed to deliver STING-R283S mRNA in pancreatic cancer immunotherapy research.

A preclinical study evaluated phenylazothiazole movable lipids added to a BNT162b2-derived mRNA lipid nanoparticle formulation and activated with programmed LED light.

A preclinical study evaluated an ICOS-targeted PET tracer for measuring immune activity during STING-agonist treatment in lung adenocarcinoma models.

A preclinical melanoma study examined a soluble recombinant protein vaccine carrying murine CD8+ and CD4+ epitopes. Its strongest finding was durable tumor control after prime-boost vaccination in the reported experimental models, while single-prime vaccination did not provide long-term control.

The SORT protocol outlines an English registry-based emulated target trial comparing radical radiotherapy and radical cystectomy after neoadjuvant chemotherapy for organ-confined muscle-invasive bladder cancer. It reports planned methods and outcomes, not comparative results.

A retrospective surgical cohort from one Chinese hospital linked several CT and demographic features with malignant solitary pulmonary nodules, but its model requires validation beyond this selected, adenocarcinoma-predominant population.

Two recent studies expose different stages of lung-screening measurement. Multiscanner CT testing found large protocol-dependent variation that was often correctable, while a small breath study identified candidate ion patterns that still require independent diagnostic validation.

Two recent studies separate major technical sources of variation in lung-screening CT from a practical preparation detail that showed no measurable penalty. Scanner-specific reconstruction settings changed dose and nodule-measurement performance, while wearing a brassiere did not worsen measured image quality or radiation dose in a paired patient study.

Two preclinical mouse studies use different antibody-centered strategies—CXCL13-expressing bacteria in bladder tumors and vaccination against tumor vasculature—to reshape immune-resistant tumor environments.

Two recent preclinical studies used very different routes—an engineered tumor-targeting nanoparticle and a microbiome-derived metabolite—to strengthen antitumor immune activity in mouse models.

Two recent studies connect a strategy for directing T cells toward intracellular tumor antigens with proteome-wide evidence that shared peptide sequences can complicate target specificity.

The IRIS trial showed imatinib, a pill targeting the BCR-ABL protein that drives chronic myeloid leukemia, far outperformed the prior standard — a template for targeted cancer therapy.

A randomized trial showed adding trastuzumab, a monoclonal antibody against HER2, to chemotherapy improved outcomes in metastatic breast cancer that overexpresses HER2.

In the ELIANA trial, a one-time infusion of a child’s own genetically reprogrammed T cells drove high remission rates in hard-to-treat B-cell leukemia.

KEYNOTE-006, a randomized phase 3 trial, found the anti-PD-1 antibody pembrolizumab improved progression-free and overall survival versus ipilimumab in advanced melanoma, with fewer severe side effects.